Mylan Pharmaceuticals Inc. is recalling 4,272 bottles of Prasugrel (5 mg) tablets, a prescription medication used to prevent blood clots. The recall was initiated because the tablets failed dissolution testing, meaning they may not dissolve properly in the body to release the medicine as intended. This defect could result in a lower-than-intended dose of the medication, which may reduce its effectiveness in preventing serious cardiovascular events. These tablets were distributed nationwide in the United States in 30-count bottles.
The tablets failed to meet the required dissolution specifications, which means the drug may not be absorbed by the body at the correct rate or amount. This poses a risk that patients may not receive the full therapeutic benefit of the medication, potentially increasing the risk of blood clots or other heart-related complications.
Healthcare consultation and pharmacy refund
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.